CONTEXT: Current and future estimates of Alzheimer disease (AD) are essential for public health planning. OBJECTIVE: To provide prevalence estimates of AD for the US population from 2000 through 2050. DESIGN: Alzheimer disease incidence estimates from a population-based, biracial, urban study, using a stratified random sampling design, were converted to prevalence estimates and applied to US Census Bureau estimates of US population growth. SETTING: A geographically defined community of 3 adjacent neighborhoods in Chicago, Ill, applied to the US population. PARTICIPANTS: Alzheimer disease incidence was measured in 3838 persons free of AD at baseline; 835 persons were evaluated for disease incidence. Main Outcome Measure Current and future estimates of prevalence of clinically diagnosed AD in the US population. RESULTS: In 2000, there were 4.5 million persons with AD in the US population. By 2050, this number will increase by almost 3-fold, to 13.2 million. Owing to the rapid growth of the oldest age groups of the US population, the number who are 85 years and older will more than quadruple to 8.0 million. The number who are 75 to 84 years old will double to 4.8 million, while the number who are 65 to 74 years old will remain fairly constant at 0.3 to 0.5 million. CONCLUSION: The number of persons with AD in the US population will continue to increase unless new discoveries facilitate prevention of the disease.
CONTEXT: Current and future estimates of Alzheimer disease (AD) are essential for public health planning. OBJECTIVE: To provide prevalence estimates of AD for the US population from 2000 through 2050. DESIGN:Alzheimer disease incidence estimates from a population-based, biracial, urban study, using a stratified random sampling design, were converted to prevalence estimates and applied to US Census Bureau estimates of US population growth. SETTING: A geographically defined community of 3 adjacent neighborhoods in Chicago, Ill, applied to the US population. PARTICIPANTS: Alzheimer disease incidence was measured in 3838 persons free of AD at baseline; 835 persons were evaluated for disease incidence. Main Outcome Measure Current and future estimates of prevalence of clinically diagnosed AD in the US population. RESULTS: In 2000, there were 4.5 million persons with AD in the US population. By 2050, this number will increase by almost 3-fold, to 13.2 million. Owing to the rapid growth of the oldest age groups of the US population, the number who are 85 years and older will more than quadruple to 8.0 million. The number who are 75 to 84 years old will double to 4.8 million, while the number who are 65 to 74 years old will remain fairly constant at 0.3 to 0.5 million. CONCLUSION: The number of persons with AD in the US population will continue to increase unless new discoveries facilitate prevention of the disease.
Authors: Anthony V Pensa; Maris A Cinelli; Huiying Li; Georges Chreifi; Paramita Mukherjee; Linda J Roman; Pavel Martásek; Thomas L Poulos; Richard B Silverman Journal: J Med Chem Date: 2017-08-04 Impact factor: 7.446
Authors: Patricia L Kramer; Haiyan Xu; Randall L Woltjer; Shawn K Westaway; David Clark; Deniz Erten-Lyons; Jeffrey A Kaye; Kathleen A Welsh-Bohmer; Juan C Troncoso; William R Markesbery; Ronald C Petersen; R Scott Turner; Walter A Kukull; David A Bennett; Douglas Galasko; John C Morris; Jurg Ott Journal: Neurobiol Aging Date: 2010-05-07 Impact factor: 4.673
Authors: B K Binukumar; Ya-Li Zheng; Varsha Shukla; Niranjana D Amin; Philip Grant; Harish C Pant Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: P Mendiratta; J M Tilford; P Prodhan; K Curseen; G Azhar; Jeanne Y Wei Journal: Am J Alzheimers Dis Other Demen Date: 2012-10-04 Impact factor: 2.035
Authors: Nicolette S Honson; Ronald L Johnson; Wenwei Huang; James Inglese; Christopher P Austin; Jeff Kuret Journal: Neurobiol Dis Date: 2007-07-28 Impact factor: 5.996
Authors: Lars G Fritsche; Robert N Fariss; Dwight Stambolian; Gonçalo R Abecasis; Christine A Curcio; Anand Swaroop Journal: Annu Rev Genomics Hum Genet Date: 2014-04-16 Impact factor: 8.929